The possibility of angiogenesis inhibition in cutaneous melanoma by Bevacizumab-loaded lipid-chitosan nanoparticle

Abstract

Cutaneous malignant melanoma is fastest-growing cancer in white populations with a large majority of dermal cancer death. The activity of vascular endothelial growth factors (VEGFs) results in the signaling of a variety of downstream intracellular pathways that ultimately leads to cell activation, proliferation, migration, and angiogenesis. VEGF inhibitors such as Bevacizumab are widely used in chemotherapy with systemic administration, which in many cases is associated with a variety of side effects. Here, we designed and synthesized a lipid-polymer nanoparticle for local administration of Bevacizumab. Drug release, dermal absorption, and the effects of synthesized nanoparticles containing Bevacizumab on cell proliferation and in vitro and in vivo angiogenesis were investigated. Encapsulating Bevacizumab in the synthesized nanoparticles resulted in a significant increase in its dermal absorption compared to free Bevacizumab. Also, the suppressor effects of Bevacizumab encapsulated in the synthesized nanoparticle on cell proliferation and angiogenesis were significantly more than those of free Bevacizumab. Our findings indicate the remarkable effects of lipid-polymer nanoparticles in dermal absorption and in maintaining Bevacizumab bioactivity, suggesting therapeutic benefits of local Bevacizumab administration for angiogenesis-related disorders such as cutaneous melanoma.